© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Obstetrics-Gynecology & Women's Health
Individualizing UF Therapy
May 06, 2022
Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.
Addressing Unmet Needs in UF
May 06, 2022
Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.
Unmet Needs for UF Treatment
April 29, 2022
Drs Lopes and Al-Hendy describe the unmet needs they see when treating patients with UF.
Healthcare Disparities in Women’s Reproductive Health
April 29, 2022
Dr Maria Lopes provides an overview of common disparities seen when treating and maintaining women’s reproductive health and how these can be minimized.
Managing UF Treatment
April 22, 2022
Dr Lopes discusses the typical payer challenges with managing UF treatment, including pain management.
GnRH Receptor Antagonists in UF
April 22, 2022
Dr Al-Hendy highlights the oral GnRH receptor antagonists as first-line therapy for UF.
UF Treatment Goals
April 18, 2022
Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.
A Changing Treatment Paradigm in UF
April 18, 2022
Dr Ayman Al-Hendy details the shift from surgical options to medical therapy for patients with UF.
UF Risk Factors
April 08, 2022
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, elaborates on risk factors for the development of UF.
The Economic Burden of UF
April 08, 2022
Maria Lopes, MD, discusses the economic burden of UF from a payer’s perspective, explaining direct and indirect costs associated with the condition.